Thousands of adults suffering from severe hair loss due to alopecia areata could soon experience significant hair regrowth following the recent approval of a new oral treatment in Britain. The UK's medicines watchdog, the MHRA, has granted approval to deuruxolitinib, also known as Leqselvi, for individuals with severe alopecia areata, offering a beacon of hope for those grappling with this distressing autoimmune condition.

Alopecia areata, affecting approximately one in 500 people, is a condition where the body's immune system mistakenly attacks hair follicles, leading to hair loss in patches on the scalp, face, and other parts of the body. While it can manifest at any age, it is most prevalent in early adulthood and can be triggered by factors such as stress, viral infections, or underlying health problems. Over time, celebrities like Jada Pinkett Smith, Louis Theroux, and Matt Lucas have publicly shared their experiences with alopecia, contributing to increased awareness of the condition. Approximately two percent of the population will experience some form of alopecia in their lifetime, with about one in every 4,000 developing alopecia areata annually. Hair follicles are not destroyed but become dormant, making regrowth a possibility, although the extent and duration of hair loss can vary widely, and hair regrowth is often unpredictable.

The newly approved treatment, deuruxolitinib, functions by reducing inflammation and preventing the immune system from damaging hair follicles, thereby enabling hair to grow back. In comprehensive clinical trials involving over 1,200 adults with alopecia areata, all participants had experienced at least 50 percent scalp hair loss for more than six months. Patients were administered either an 8mg dose of the drug twice daily or a placebo pill over 24 weeks. The results were highly promising: after six months, those receiving deuruxolitinib demonstrated significantly more hair regrowth compared to the placebo group. Nearly a third of patients achieved at least 80 percent regrowth of their scalp hair, while almost one in four saw 90 percent or more regrowth during the trial period. The most commonly reported side effects included headaches and acne, affecting more than one in ten patients.

Julian Beach, executive director for healthcare quality and access at the MHRA, stated that this approval provides another valuable treatment option for individuals managing alopecia areata, emphasizing the MHRA's commitment to continuously monitor the drug's safety and effectiveness. Currently, Leqselvi is available only with a private prescription in the UK. Its availability through the NHS is contingent upon assessment by the National Institute for Health and Care Excellence (NICE), which will determine if the treatment offers good value for money.

The emotional impact of alopecia can be profound, often leading to loss of confidence and significant anxiety about appearance. This new treatment offers a substantial psychological benefit and renewed hope for thousands of sufferers. It is not the sole recent advancement in treating the condition; in 2024, Ritlecitinib, a once-daily 50mg oral capsule manufactured by Pfizer, was approved for severe alopecia areata in adolescents and adults. Ritlecitinib, also a janus kinase (JAK) inhibitor, works by dampening the immune system and reducing enzymes that cause inflammation and hair loss at the follicle, and has been recommended by NICE for those aged 12 and over.